COVID-19 update: The race to therapeutic development
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), represents an unprecedented challenge to global public health. At the time of this review, COVID-19 has been diagnosed in over 40 million cases and associated with 1.1 million deaths worldwide. Current mana...
- Autores:
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/15342
- Acceso en línea:
- https://doi.org/10.1016/j.drup.2020.100733
http://hdl.handle.net/20.500.12010/15342
- Palabra clave:
- COVID-19
SARS-CoV-2
Virus life cycle
Herapeutic targets
Drug development
Antivirals
Immunomodulators
Monoclonal antibodies
ACE2
Spike protein
Repurposed use
Existing drugs
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
- Rights
- License
- Abierto (Texto Completo)